AI Article Synopsis
- Diffuse large B-cell non-Hodgkin lymphoma (DLBCL) primarily affects older individuals, but most treatment guidelines are based on studies of younger patients.
- With a significant rise in the elderly population, especially those over 75, it's crucial to tailor treatment strategies for these patients to enhance their outcomes.
- This review highlights key challenges in treating older patients, summarizes important studies focused on this demographic, and proposes an algorithm to help healthcare providers make informed treatment decisions for DLBCL patients older than 80.
Article Abstract
Diffuse large B-cell non-Hodgkin lymphoma (DLBCL) is a disease of the elderly, but our current guidelines and treatment paradigms for this disease are based on studies that have mainly enrolled younger patients. Because the number of people living beyond the age of 80 increased by more than 250% between 1960 and 2000, and since it is expected that the population over the age of 75 will triple by 2030, understanding how these elderly patients should be treated is paramount to improving outcomes for this potentially curable lymphoma. In this review, we outline the scope of the problem; we define "the elderly" and identify challenges in assessing this patient population. We also summarize pivotal studies that have been conducted in these elderly patients and suggest an algorithm to aid clinicians in making treatment decisions when faced with DLBCL patients older than 80.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!